Cardio Diagnostics Holdings, Inc. (CDIO)
NASDAQ: CDIO · Real-Time Price · USD
0.248
+0.003 (1.33%)
Nov 21, 2024, 1:22 PM EST - Market open

Company Description

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.

It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.

Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings logo
Country United States
Founded 2017
Industry Biotechnology
Sector Healthcare
Employees 9
CEO Meeshanthini Dogan

Contact Details

Address:
311 West Superior Street, Suite 444
Chicago, Illinois 60654
United States
Phone 302 281 2147
Website cardiodiagnosticsinc.com

Stock Details

Ticker Symbol CDIO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001870144
CUSIP Number 14159C103
ISIN Number US14159C1036
Employer ID 87-0925574
SIC Code 2835

Key Executives

Name Position
Dr. Meeshanthini V. Dogan Ph.D. Co-Founder, Chief Executive Officer and Director
Elisa Michael Luqman Esq., J.D., M.B.A. Chief Financial Officer
Dr. Robert A. Philibert M.D., Ph.D. Co-Founder, Chief Medical Officer and Director
Timur Dogan Ph.D. Chief Technology Officer
Khullani Abdullahi J.D. Vice President of Revenue and Strategy

Latest SEC Filings

Date Type Title
Nov 18, 2024 8-K Current Report
Nov 13, 2024 10-Q Quarterly Report
Oct 4, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Oct 4, 2024 DEF 14A Other definitive proxy statements
Sep 25, 2024 ARS Filing
Sep 23, 2024 PRE 14A Other preliminary proxy statements
Sep 5, 2024 EFFECT Notice of Effectiveness
Aug 30, 2024 POS AM Post-Effective amendments for registration statement
Aug 12, 2024 10-Q Quarterly Report
Jun 7, 2024 8-K Current Report